Mayo Clinic Investigator Discusses Remaining Questions on AstraZeneca’s PACIFIC Clinical Trial in Lung Cancer

Mayo Clinic Investigator Discusses Remaining Questions on AstraZeneca’s PACIFIC Clinical Trial in Lung Cancer

Sponsored by AstraZeneca, the PACIFC study was a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study of MEDI14736 (durvalumab) as Sequential Therapy in Patients with Locally advanced, unresectable non-small cell lung cancer (stage 3) who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy. The PACIFIC trial evidenced the addition of durvalumab (Imfinzi) as consolidation therapy significantly improved progression-free survival and overall survival versus placebo in patients with stage III NSCLC who did not have disease progression after 2 or more cycles of platinum-based chemoradiation. Following this study, more patients with stage III NSCLC should be eligible for immunotherapy.

The Study

The study was a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study of MEDI4736 as Sequential Therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (PACIFIC).

The Results

TrialSite News offers a link to Dr. Konstantinos Leventakos, MD, assistant professor of oncology, Mayo Clinic, on the impact of the PACIFIC trial on the stage III non-small cell lung cancer (NSCLC) treatment in Onclive to discuss the results via a video. We note that questions on this study and associated treatment remain.

Study Sponsor

AstraZeneca

About MEDI14736

MEDI4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumor’s immune-evading tactics. MEDI4736 is being developed, alongside other immunotherapies (IMTs), to empower the patient’s immune system and attack the cancer. The PACIFIC clinical trial was a global study to assess the effects of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer.

Lead Research/Investigator

Dr. Konstantinos Leventakos, MD assistant professor of oncology, Mayo Clinic

Call to Action: Are you tracking lung cancer (NSCLC)? Dr. Leventakos is a global expert conducting clinical research out of one of the world’s top providers and investigator site Mayo Clinic.